Accelerating Physiatry (PM&R) Biologics Prior Auth

The Challenge of Biologics Prior Auth in Physiatry

Physiatry (PM&R) often manages patients with chronic inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, where biologics are essential for disease modification and functional improvement. These specialty medications, including TNF inhibitors, IL-17/23, IL-6, and JAK inhibitors, represent a substantial share of high-cost drug prior authorizations. The administrative burden stems from the detailed clinical documentation required to justify medical necessity against evolving payer policies.

Key Prior Authorization Triggers for PM&R Biologics

Prior authorization for biologics in rehabilitation medicine is typically triggered by several factors. These include indication-specific criteria aligning with clinical guidelines, stringent step therapy requirements mandating trials of less costly alternatives, and payer policies around biosimilar substitution. Additionally, documentation of pre-screening requirements (e.g., TB, hepatitis) and periodic re-authorization for chronic treatment cycles are common PA points for these high-value therapies.

Klivira's Automated Workflow for Physiatry Biologics PA

• **Indication Classification:** Automatically identifies the specific specialty and disease state (e.g., spondyloarthropathy, psoriatic arthritis) from EMR diagnoses to apply relevant PA criteria.
• **Step Therapy Automation:** Pulls prior-line therapy history (e.g., failed NSAIDs, conventional DMARDs) from EMR data, submitting documentation required by payer step therapy protocols.
• **Biosimilar Substitution Routing:** Applies per-payer biosimilar mandates, guiding the authorization process based on required biosimilar trials or preferences.
• **Screening Documentation:** Extracts and organizes critical screening results (TB PPD or IGRA, hepatitis B/C, immunization status) from FHIR-enabled EMR data.
• **Periodic Re-authorization:** Manages typical 6- or 12-month re-authorization cycles, prompting for continuous disease activity and response documentation from the EMR.
• **Medical-vs-Pharmacy Benefit Routing:** Accurately routes prior authorization requests based on whether the specific biologic agent and administration mode fall under the medical or pharmacy benefit.

EMR and Payer Touchpoints in Rehabilitation Medicine Biologics PA

Effective biologics prior authorization in PM&R relies on seamless integration with EMR systems and diverse payer channels. Klivira leverages structured data from EMRs for diagnoses, lab results, medication history, and functional assessments. For payer connectivity, we utilize standard channels like X12 278 transactions, ePA platforms, and direct payer portal integrations. This ensures that all necessary clinical context, often informed by guidelines from bodies like the American College of Rheumatology (ACR), is accurately transmitted.

Achieving Operational Efficiency with Klivira in PM&R

Implementing Klivira's prior authorization automation for physiatry (PM&R) biologics enables clinics and health systems to significantly reduce manual effort, accelerate approval times, and minimize denials. By automating the collection of clinical evidence, managing step therapy, and streamlining re-authorization processes, Klivira helps ensure consistent compliance considerations and improves patient access to essential, high-cost therapies. This operational efficiency translates to improved revenue cycle performance and enhanced patient satisfaction.